Fractyl Laboratories completed a new equity offering

For more information and other transactions visit
XDATA – November 6th 2015
Fractyl Laboratories issued equity for a total of $37.17 million in a non-brokered investment round. The transaction which started on October 23rd, garnered the support of sixteen investors. Two previous unregistered financing rounds raised an estimated $62.98 million.
Fractyl Laboratories develops a minimally invasive, device-based, implant-free duodenal mucosal resurfacing procedure (Revita DMR) that directly addresses the intestinal hormonal impairment that contributes to insulin resistance and changes how the body absorbs and processes sugar. The company is backed by Mithril Capital Management, General Catalyst, Bessemer Venture Partners, and Domain Associates.
The company, led by Harith Rajagopalan, is headquartered in Waltham MA. Fractyl Laboratories elected to keep its revenues undisclosed.
The executive team includes Jay Caplan and Lisa Davidson.
The board of directors includes Ajay Royan, Allan Will, Christopher Gabrieli, Nimesh Shah and Stanley Lapidus.

The company has raised an estimated total of $100.15 million via private unregistered security offerings.

Offering recap
Status: Completed
Company: Fractyl Laboratories
Industry: Other Health Care
Amount offered: $37.17 million
Amount placed: $37.17 million
SEC filing: Source
First sale: 10-23-2015
Data as of: 11-06-2015

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s